HDB Compound Collections
•
Ready-to-use libraries with over 50,000
compounds
•
A collection of both commercial and in-
house developed unique libraries
•
Highly diversified screening tools and
formats provide a greater hit probability
To find a leading compound with appropriate interaction in biological models, it is a common approach to screen a drug target against a selection of chemicals. High quality compound library provides a better chance that high-throughput screening (HTS) will identify a "hit". HDB owns a combination of commercial and in-house libraries, advanced cloud-based chemo-informatics compound management system and rich experiences in
assay development.
FDA approved drug library
-
A unique collection of 1,370 FDA approved drugs providing an ideal research tool for
new targets of old drugs
-
A collection of 14,400 premier compounds representing the drug-like diversity of the
Maybridge screening set
-
 Offering ready-to-use of easy & rapid lead identification
-
Up to 35,000 fragments with low cLogP (MW≤300 Da; cLogP≤3), allowing structural-
based lead identification
-
 Pharmacaphore rich yet simple for interpretation of the results
-
Dynamic growing number of compound collection synthesized via modern methodology
-
 Novel and unique chemical space in structures not found in commercial
-
 Hit-rich potential through HTS screenings against various targets classess
-
Compound management system enables smooth operation of HTS/SAR campaigns
-
Medicinal chemistry supports hit follow-ups, hit expansion and lead optimization
-
Comprehensive platforms of HTS, SAR screening, off target evaluation and drug property
profiling
-
Outstanding track record of pharmaceutical, biotech and startup collaboration and
partnership
To receive more information on HDB compound libraries and related services, please contact us.
Related Services
HTS and Compound Management
Medicinal Chemistry
The Latest Generation of Auto Patch Clamp Platform Launched at HDB
----------------------
WuXi Biology/HD Biosciences Presented at Webinar of "New Technologies for Target Discovery and Validation"
----------------------
HD Biosciences Merges with WuXi AppTec
HD Biosciences (China) Co.,Ltd
590 Ruiqing Road
Zhangjiang East Campus, Pudong, Shanghai 201201,
P.R.China
Tel: +86 (21) 5116 3700
Fax: +86 (21) 5116 3766
SERVICES
|
THERAPEUTIC AREAS
|
NEWS & EVENTS